Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-20-005116
Filing Date
2020-04-17
Accepted
2020-04-17 16:28:38
Documents
8
Period of Report
2019-12-31
Effectiveness Date
2020-04-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A mirati2020proxy.htm DEF 14A 891176
2 a2020mrtxvotingcard01.jpg GRAPHIC 48395
3 a2020mrtxvotingcard02.jpg GRAPHIC 55827
4 a2020mrtxvotingcard03.jpg GRAPHIC 24763
5 a2020mrtxvotingcard04.jpg GRAPHIC 53832
6 chuckbaummanualsignature.jpg GRAPHIC 3453
7 danfagamanualsignature.jpg GRAPHIC 11183
8 miratitherapeuticslogoblack.jpg GRAPHIC 15885
  Complete submission text file 0001628280-20-005116.txt   1154564
Mailing Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Filer) CIK: 0001576263 (see all company filings)

EIN.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35921 | Film No.: 20800068
SIC: 2834 Pharmaceutical Preparations